Scientist​/Sr. Scientist, DMPK

General Proximity is a seed‑stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co‑opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades.

A long‑standing challenge in drug discovery is the development of molecules capable of modulating difficult or “undruggable” targets. Disease‑causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA‑approved drugs is inhibition[1], but there are many other possible perturbation types whose potential remains unrealized.

General Proximity is a seed‑stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach).

Historically, the development of technologies that allow one to push new buttons in biology has been an incredibly fertile field for the discovery of new medicines[2, 3, 4], and our technology holds the same promise.

We are seeking an exceptional DMPK expert to join and lead our drug metabolism and pharmacokinetics function. This is a hands‑on, high‑impact role in which you will design and execute DMPK studies across our small molecule portfolio, interpret and communicate data to project teams, and serve as a key DMPK contributor in cross‑functional settings.

You will help shape scientific approaches, support regulatory activities, and play an important role in advancing programs from lead optimization through IND. You will work closely with our medicinal chemistry, structural biology, pharmacology, and toxicology teams to translate DMPK science into actionable program decisions.

The ideal candidate is a hands‑on scientist who combines solid technical expertise in ADME, in vivo PK, and PK/PD modeling with the ability to work independently and collaborate effectively across teams. This role is well suited for someone with a few years of DMPK experience at a pharma or biotech who now wants to take on greater ownership and grow at a mission‑driven company working at the frontier of induced proximity medicine.

This role benefits from familiarity with the unique DMPK challenges of induced proximity medicines and bifunctional molecules. These include non‑linear and dose‑dependent pharmacokinetics arising from ternary complex formation, linker and warhead metabolic soft spots, high molecular weight and physicochemical complexity affecting permeability and oral bioavailability, tissue distribution considerations for proteasome‑engaging degraders, and the interpretation of hook‑effect phenomena in in‑vitro and in‑vivo settings.

Exposure to TPD, molecular glue, PROTAC, or other bifunctional modality DMPK is a plus for this role.

Design, execute, and interpret in vitro ADME studies, including metabolic stability, CYP inhibition/induction, plasma protein binding, permeability (Caco-2/MDCK), solubility, and transporter assays.

Contribute to in vitro–in vivo correlation (IVIVC) analyses to inform candidate selection and advance structure–activity/property relationships.

Interpret metabolic soft spot and MetID data, translating findings into actionable guidance for medicinal chemistry teams.

Support CRO relationships for outsourced ADME studies, including scientific oversight of study execution and data quality review.

Support bioanalytical activities for the portfolio, including CRO-performed LC-MS/MS method development for small molecules and their metabolites across biological matrices.

Help ensure GLP‑compliant bioanalytical practices for IND‑enabling studies and monitor regulated bioanalysis timelines and data quality through CRO partners.

Contribute to fit‑for‑purpose bioanalytical approaches for induced proximity molecules, including strategies for quantifying bifunctional compounds and target engagement biomarkers.